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provided it is propeObjective: To describe immunologic, virologic, and clinical HIV disease progression
by HIV-1 subtype among Africans with well documented estimated dates of HIV
infection (EDIs).
Design: Prospective cohort.
Methods: Adults and youth with documented HIV-1 infection in the past 12 months
were recruited from seroincidence cohorts in East and Southern Africa and followed at
3–6 month intervals. Blood for lymphocyte subset and viral load determination was
collected at each visit. Pol was sequenced from the first positive specimen to ascertain
subtype. Preantiretroviral therapy disease progression was measured by three time-to-
event endpoints: CD4þ cell count 350 cells/ml or less, viral load measurement at least
1105 copies/ml, and clinical AIDS.
Results: From 2006 to 2011, 615 participants were enrolled at nine research centers in
Kenya, Rwanda, South Africa, Uganda, and Zambia; 579 (94.1%) had viral subtyping
completed. Predominant subtypes were C (256, 44.2%), A (209, 36.1%), and D (84,
14.5%). After adjustment for age, sex, and human leukocyte antigen alleles in Cox
regression analyses, subtype C-infected participants progressed faster than subtype A to
all three endpoints [CD4þ hazard ratio 1.60, 95% (confidence interval) CI 1.16, 2.20;
viral load hazard ratio 1.59, 95% CI 1.12, 2.25; and AIDS hazard ratio 1.60, 95% CI
1.11, 2.31). Subtype D-infected participants reached high viral load more rapidly
(hazard ratio 1.61, 95% CI 1.01, 2.57) and progressed nearly twice as fast to AIDS
compared to subtype A (hazard ratio 1.93, 95% CI 1.21, 3.09).
Conclusion: Subtype-specific differences in HIV disease progression suggest that the
local subtype distribution be considered when planning HIV programs and designing
and defining clinical endpoints for HIV prevention trials.
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2776 AIDS 2013, Vol 27 No 17IntroductionAlthough several efficacious HIV prevention interven-
tions have been identified [1], their impact has been
insufficient to end the pandemic. Improved methods,
including a well tolerated and efficacious preventive
vaccine, are needed. HIV type 1 (HIV-1) uses myriad
strategies to evade host immune defenses. HIV-1 mutates
rapidly, generating multiple subtypes (A–D, F–H, and J),
six sub-subtypes (A1–4 and F1–2), circulating recombi-
nant forms, and unique recombinant forms of HIV-1
Group M worldwide [2]. Sub-Saharan Africa (SSA) is
home to only 12% of the world’s population [3], yet
carries the burden of 72% of HIV-infected individuals [4].
With its diversity in HIV virology, human genetics, and a
heterogeneous epidemic, understanding HIV epidemio-
logy in Africa is vital to characterize the interplay
between viral subtype and host immunology.
HIV disease progression has been well described for
HIV-1 subtype B in Europe and North America [5–7],
subtype B0 and CR01_AE (formerly subtype E) in
Thailand [8,9], subtype C in India and Brazil [10–12],
HIV-1 subtypes G and F in West Africa [13], and HIV-2
in west Africa [14]. The epidemiology and disease course
in East and Southern Africa, where HIV-1 subtypes A, D,
and C predominate [2], have also been characterized
[15–19]. Subtype C predominates in Southern Africa,
where HIV prevalence is higher than in East Africa, for
reasons that may include differential transmissibility or
pathogenesis. Direct comparison between subtype C and
other subtypes is less available. Published data describe
HIV-1 to be more pathogenic than HIV-2, HIV-1
subtype D to be more pathogenic than subtype A
[15–17,19–23], and subtype C more pathogenic than A
and D [24].
In preparation for HIV vaccine efficacy trials in SSA, the
International AIDS Vaccine Initiative (IAVI) partnered
with research centers in Kenya, Rwanda, South Africa,
Uganda, and Zambia to develop prospective HIV
incidence cohorts of adult participants at risk for
HIV-1. We describe the immunologic, virologic, and
clinical disease progression for HIV in this cohort.Methods
Ethical considerations
All participants provided informed consent. This study
was approved by: the Kenya Medical Research Institute
Ethical Review Committee, the Kenyatta National
Hospital Ethical Review Committee of the University
of Nairobi, the Rwanda National Ethics Committee, the
Uganda Virus Research Institute Science and Ethics
Committee, the Uganda National Council of Science and
Technology, the University of Cape TownHealth Sciencepyright © Lippincott Williams & Wilkins. UnauthoResearch and Ethics Committee, the University of
Zambia Research Ethics Committee, the Bio-Medical
Research Ethics Committee at the University of
KwaZulu Natal, and the Emory University Institutional
Review Board.
Study population and clinical procedures
This is a prospective, multicenter cohort study of HIV-
infected men and women aged 16–60 years with recent
HIV infection of known duration. The network
comprised nine clinical research centers (CRCs) in five
countries (Kenya: the Kenya Medical Research Institute/
Centre for Geographic Medicine Research – Coast,
Kilifi, and Mtwapa, and University of Nairobi Kenya
AIDS Vaccine Initiative, Nairobi; Rwanda: Project San
Francisco, Kigali; South Africa: University of Cape Town
Desmond Tutu HIV Centre, Cape Town, and The
Aurum Institute, Rustenburg Research Centre; Uganda:
Medical Research Council of Uganda, Masaka, and the
Uganda Virus Research Institute/IAVI program,
Entebbe; Zambia: Zambia-Emory HIV Research Pro-
ject, Lusaka, Ndola, and Kitwe).
Study eligibility required a documented HIV-negative
test within the previous year and a subsequent HIV-
positive test. Study participants were primarily recruited
from prospective incidence cohorts of HIV-negative
individuals who received HIV prevention counseling
and testing and condoms quarterly or monthly. Key
populations included HIV-negative members of HIV-
serodiscordant couples, men who have sex with men
(MSM), youth (16–24 years), men or women who
reported a recent sexually transmitted infection (STI) or
unprotected sex with multiple partners in exchange for
money or gifts, and women from high prevalence
communities. A few participants (6%) were recruited
from HIV voluntary counseling and testing centers.
Participants with a positive p24-antigen ELISA or HIV-
antibody test were invited to enroll. The estimated date of
HIV infection (EDI) was defined as the midpoint
between the last negative and first positive HIV-antibody
test, 14 days before the first positive p24 antigen test,
10 days before the first positive viral load test in the
absence of p24 antigen or rapid HIV antibodies, or the
date of a high-risk exposure event. All HIV-1 infection
was confirmed by viral load testing.
Participants were seen monthly until 3 months after EDI,
then quarterly until 24 months, and semiannually
thereafter. Participants underwent a complete (entry
visit) or symptom-directed physical examination and a
detailed complete or interim medical history including
onset of HIV-related illness, a blood draw, and a urine
pregnancy test (women). Participants were provided
acute clinical care at the study clinic or referred for
treatment as needed. Non-HIV STIs were managed
syndromically or treated per national guidelines. If HIVrized reproduction of this article is prohibited.
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near the CRC, study participants were referred. Other-
wise, HIV care, including ART, was provided by the
CRC.
Laboratory procedures
Laboratory equipment and procedures were standardized
across CRCs. Study clinic staff were trained in good
clinical practice (GCP) and laboratory staff in good
clinical laboratory practices (GCLP) [25]. Laboratories
that performed study procedures participated in internal
and external quality control and assurance processes and
were GCLP accredited.
Laboratory testing including CD4þ cell counts and
routine laboratory tests were conducted at the CRCs and
viral load testing [Roche Amplicor Monitor v1.5; Roche
Diagnostics, Indianapolis, USA (February 2006–January
2011) or Abbott Real Time HIV-1 v1.0 Abbott
Molecular Diagnostics, Mississauga, Canada, thereafter]
at Clinical Laboratory Services, Johannesburg [26]. A
positive annual syphilis test [rapid plasma reagin, Biotec
Laboratories, Inc., UK] was confirmed by Treponema
pallidum hemagglutination assay. Abnormal urinalysis was
investigated by microscopy.
All p24-positive, antibody negative specimens were
repeat tested, and, if positive, early HIV infection was
suspected [27]. If participants did not report ART but
showed an abrupt drop in viral load to less than 2000
RNA copies/ml, antiretroviral drug level testing was
conducted on the first available sample following the drop
[26].
HIV-1 viral subtype analysis
The REGA HIV-1 subtyping tool (http://hivdb.
stanford.edu/) was used to analyze sequence from the
pol gene from the first specimen after HIV-infection [26].
Additional phylogenetic analysis was done if REGA
results were indeterminate.
Human leukocyte antigen class I testing
Human leukocyte antigen (HLA) genotyping included
HLA-A, HLA-B, and HLA-C, as described by Tang et al.
[28]. Allelic variants were resolved to four-digit
specificities using PCR and defined according to current
guidelines [28].
Data and statistical analyses
Data were collected on case report forms, verified, and
faxed (Clinical DataFax Systems, Inc., Hamilton, Canada)
to a central database at Perinatal HIV Research Unit,
University of Witswatersrand, Johannesburg RSA. Data
analyses were conducted using STATA version 12
(Stata Corporation, College Station, Texas, USA) and
R version 2.15.0 (http://CRAN.R-project.org).Copyright © Lippincott Williams & Wilkins. UnautDemographic variables, method to determine EDI, and
baseline characteristics were summarized by HIV-1
subtype. For continuous variables, the median and
interquartile range was determined. The F-test of no
difference in themean values across infecting subtypes was
performed. For categorical variables, the frequencies and
percentages were calculated. Pearson’s chi square test of
no association between response and subtype was
conducted. Variables associated with infecting subtype
were considered potential confounders in subsequent
analyses. MSM were examined as a separate category to
evaluate potentials subgroup differences.
Disease progression was measured by three endpoints:
immunologic, virologic, and clinical. Immunologic
progression was defined as time from EDI to the first
of two consecutive CD4þ cell counts 350 cells/ml or less.
Virologic progression was defined as time from EDI to
the first of two consecutive viral load measurements at
least 1 105 copies/ml. Clinical progression was defined
by the 1993 CDC definition for AIDS [29], or the time
from EDI to the first occurrence of a Category C event, a
CD4þ cell count lower than 200 cells/ml, or a CD4%
lower than 14. To avoid confounding by the transient
events of acute infection, CD4þ cell counts and viral load
measurements from the first 69 days post-EDI were
excluded from analysis. Day 70 begins the window for the
month 3 visit, by which time viral load should be past its
initial peak and CD4þ cell count past its acute phase nadir
[30]. Except for those on short-course antiretroviral drug
for prevention of mother-to-child HIV transmission,
participants were censored at time of self-reported ART
initiation or detection of blood antiretroviral drug levels.
To evaluate the potential bias of early or late ART
initiation or any country or regional differences in ART
provision, the endpoint of time to CD4þ cell count
350 cells/ml or less or ART initiation was also examined.
The log-rank test was used to assess the association
between infecting HIV-1 subtype and disease progression
without stratification for baseline covariates. Using
subtype A-infected participants as the referent group,
Cox proportional hazards models were applied for all
three endpoints, if HLA results and at least one CD4þ cell
count and viral load measurement after day 70 post EDI
were available. Unadjusted and adjusted analyses were
performed to assess baseline covariates of age at EDI, sex,
risk group, BMI, male circumcision, delayed enrolment
(more than 6 months post-EDI), education, hemoglobin,
marital status, method of HIV detection, report of acute
retroviral syndrome, source of recruitment, and HLA
type on risk of disease progression. Baseline variables
significant in univariate analysis were included in the final
adjusted model.
Linear mixed effects models were used to assess the
change in log10 transformed and untransformed CD4
þ
cell count after day 70. Visual inspection of CD4þ cellhorized reproduction of this article is prohibited.
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months 3 and 12 versus after month 12. A piecewise
linear mixed effects model of CD4þ cell count over time
with a single knot at month 12 was fit to the data. HIV-1
subtype, age group, sex, and risk group were examined as
fixed effects. All models included a random intercept and
slope for each participant to account for individual set
points and correlated outcomes. An individual’s intercept
and slope were assumed uncorrelated. Other knots for
change in CD4þ cell count were explored.
Several types of sensitivity analyses were performed.
Analyses restricted to East African cohorts were
performed to assess potential confounding by geographic
location. Because preinfection CD4þ cell counts were
not measured, CD4þ cell count at month 3 was examined
as a predictor of disease progression. Although CD4þ cell
count and viral load at month 3 were highly predictive of
disease progression, they were excluded from the final
Cox models because both reflect disease progression. The
Cox models were restricted to participants from
discordant couples only and to volunteers with and
without delayed enrollment, to assess the robustness of the
study’s conclusions.Results
Cohort description and follow-up
From February 2006 to December 2011, 615 participants
with incident HIV infection enrolled: 256 (41.6%)
women, 92 (15.0%) MSM, and 264 (42.9%) from
Southern Africa. The majority (74.8%) was enrolled from
HIV-serodiscordant couple cohorts. The median age at
EDI was 29 years (range 16–58); men were older than
women (median 31 versus 27 years, respectively,
P< 0.001). Three participants were adolescents at the
time of enrolment; all were women, from Cape Town,
and aged 16 (1) or 17 (2) years. (See Table, Supplemental
Digital Content, http://links.lww.com/QAD/A402,
which shows the population characteristics for all 615
enrolled volunteers.)
The median time from EDI to enrolment was 54 days
(range: 10–388). From 2005 to 2006, 78 (12.7%)
participants diagnosed with HIV infection before study
initiation delayed enrolment by 6 months to 1 year. The
study included 1790 person-years of ART-free follow-up
after EDI (median per-volunteer person-years duration
2.8, range 0.1–6.9 years).
Overall, 204 participants discontinued follow-up. Forty-
seven (23.0%) initiated ART, 41 (20.1%) were lost to
follow-up for unknown reasons, 33 (9.3%) were dropped
due to CRC closure, 27 (13.2%) were discontinued per
investigator discretion, 22 (10.8%) moved out of the study
area, 16 (7.8%) died, 14 (6.97.3%) withdrew voluntarily,pyright © Lippincott Williams & Wilkins. Unauthoand four (2.0%) were incarcerated. Of the 16 deaths,
seven were AIDS-related.
Infecting HIV-1 subtype
Viral subtyping was available for 579 (94.1%) participants.
The predominant HIV-1 infecting subtypes were C (256,
44.2%), A (209, 36.1%), and D (84, 14.5%). Subtype was
strongly associated with geographic location and there-
fore also key population status (Table 1). The majority of
subtype C infections occurred in Southern Africa
whereas subtypes A and D predominated in East Africa.
Compared to subtype A-infected participants, subtype C
individuals were older (32 versus 28 years, from median
age at EDI) and had a lower month 3 CD4þ cell count
(503 versus 595 cells/ml). Despite small numbers, a lower
CD4þ cell count was also seen among subtype C-infected
participants when the analysis was restricted to East
Africa. (See Table, Supplemental Digital Content 1,
http://links.lww.com/QAD/A402, which shows the
Cox proportional hazards models for participants in East
Africa only.) Bivariate analysis of other baseline
characteristics showed that age at infection, sex, marital
status, education, male circumcision status, method used
to determine EDI, and 3-month viral load values among
non-MSM males were all significantly associated with
subtype (Table 1).
Disease progression
After adjustment for age, sex, and specific HLA types,
subtype C-infected participants progressed 59–60% faster
to immunologic, virologic, and clinical endpoints
compared to subtype A (Table 2). Despite similar rates
of immunologic progression to subtype A-infected
participants, subtype D-infected participants progressed
toward faster virologic progression and had nearly twice
the rate of clinical progression to AIDS. Sensitivity
analyses gave similar results. (See Table, Supplemental
Digital Content 2, http://links.lww.com/QAD/A402,
which shows the Cox proportional hazards models
among study participants from discordant couples.)
In unadjusted analyses, non-MSM showed faster immu-
nologic progression than women or MSM. This increase
was most likely due to non-MSM being older, con-
sequently having lower month 3 CD4þ cell counts. In
adjusted analysis, women, non-MSM, and MSM did not
differ in immunologic progression; however, non-MSM
had twice the rate of virologic progression and MSM had
over twice the rate of clinical progression to AIDS versus
women. Adjusted analyses combining non-MSM and
MSM (see Table, Supplemental Digital Content 3,
http://links.lww.com/QAD/A402, which shows Cox
proportional hazards models comparing all men to
women) showed no difference in immunologic pro-
gression between males and women but indicated faster
virologic and clinical progression for males.rized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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2782 AIDS 2013, Vol 27 No 17Having a B57 allele was protective against virologic and
clinical progression; allele-positive participants progressed
at a rate 61 and 70% slower than negative participants,
respectively. The effect of B57 on immunologic
progression was more modest and did not achieve
statistical significance most likely due to the small number
of participants with this allele. Conversely, presence of the
B45 allele was associated with faster immunologic andpyright © Lippincott Williams & Wilkins. Unautho
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Fig. 1. Kaplan–Meier survival curves. (a) Time to CD4R cell count—
(c) time to AIDS by HIV-infecting subtype among participants wvirologic progression. In adjusted analyses, B45-positive
participants progressed 60 and 47% faster than negative
participants, respectively, but was not associated with
a significant trend toward faster clinical progression
(Table 2). (See Table, Supplemental Digital Content 4,
http://links.lww.com/QAD/A402, which shows the
distribution of HLA types identified in the study by
infecting HIV-1 subtypes.)rized reproduction of this article is prohibited.
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Disease progression by HIV-1 subtype in Africa Amornkul et al. 2783Figure 1 shows the Kaplan–Meier curves for the
proportion of participants reaching each disease pro-
gression endpoint by infecting HIV-1 subtype and the
P-value from the corresponding log-rank test. The
significant P-values for time to CD4þ cell count
350 cells/ml or less and time to viral load at least
1 105 copies/ml reflect the different rates of progression
between subtype A-infected and C-infected participants.
However, both subtype C-infected and D-infected
participants progressed faster to AIDS than those with
subtype A.
In the analysis of clinical progression, 168 (34.2%)
participants developed AIDS. Among the AIDS cases, 28
(16.7%) experienced a Category C event before reaching
a CD4þ cell count lower than 200 cells/ml or a CD4% less
than 14% including tuberculosis (14), herpes simplex
(seven), recurrent pneumonia (four), esophageal candi-
diasis (two), and recurrent Salmonella septicemia (one).
Another 12 participants experienced Category C events
after CD4þ cell count decline. Thus, clinical progression
primarily reflects immunologic progression.
Linear mixed effects models that controlled for sex and
infecting subtype found subtype C-infected participants
had 106 18 fewer CD4þ cells at month 3 post-EDI
versus subtype A. There was no difference in month 3
CD4þ cell count between subtype D and A participants.
From months 3–12, CD4þ cell count declined by
124 10 cells/year with no difference in the rate of
decline by sex or subtype. After month 12, CD4þ cell
count declined by 13 15 cells/year. Although subtype
C-infected participants reached a CD4þ cell count of
350 cells/ml sooner than subtype A-infected participants,
this is largely due to subtype C-infected participants
having lower CD4þ cell counts at month 3 post-EDI. A
Cox regression analysis that included month 3 CD4þ cell
count showed no difference in the rate of CD4þ cell
count decline between subtype A and C individuals
[adjusted hazard ratio 1.11, 95% confidence interval (CI)
0.73–1.69].
Among the 140 (28.5%) participants initiating ART,
country-specific differences were observed in time of
ART initiation, most likely reflecting differences in
national treatment guidelines and programs. Ugandans
and Rwandans were two and three times more likely than
Kenyans to initiate ART; Zambians and South Africans
had similar rates of ARTuptake to Kenyans. Censoring of
participants who initiated ART at CD4þ cell count
higher than 350 cells/ml did not significantly change the
time to the combined endpoint of CD4þ cell count
350 cells/ml or less or ART initiation. (See table,
Supplementary Digital Content 5, http://links.lww.
com/QAD/A402, which shows the Cox regression
analysis of disease progression with the combined
endpoints of CD4 reaching 350 cells/ml or ART
initiation.)Copyright © Lippincott Williams & Wilkins. UnautJust over 10% of the cohort was enrolled more than
6 months post-EDI (Table 1); however, delayed enroll-
ment was not associated with infecting HIV subtype nor
was it associated with any of the three outcomes. The
method used to determine volunteer EDI (antibody
versus p24 versus PCR test results, or volunteer report)
was associated with infecting subtype, with a significantly
higher proportion of subtype-A infected volunteers
having their EDI determined by p24 antigen or PCR
test result (Table 1). In the multivariable analysis, this
variable was not associated with any of the three outcomes
and therefore did not appear to confound any of the
observed relationships.Discussion
This early HIV infection cohort in SSA is notable for its
size, extensive follow-up, well documented time of HIV
infection, diversity of geographic region and infecting
HIV-1 subtypes, and characterization of HLA class I
alleles. These factors allowed robust characterization of
predictors of HIV disease progression pre-ART initiation
in Africa. We observed significantly faster progression to
CD4þ cell count 350 cells/ml or less, viral load at least
1 105 copies/ml, and AIDS endpoints among subtype
C-infected versus A-infected participants, supporting
the hypothesis that HIV-1 subtype C may be more
pathogenic [24]. Subtype D-infected participants pro-
gressed significantly faster versus subtype A-infected
participants to viral load at least 1 105 copies/ml and
AIDS; there was no difference in immunologic pro-
gression.
Although they reached a CD4þ cell count of 350 cells/ml
sooner after infection than subtype A-infected partici-
pants, subtype C-infected participants also had lower
CD4þ cell counts at 3 months post-EDI. (See Table,
Supplemental Digital Content 6, http://links.lww.com/
QAD/A402, which shows median CD4þ cell counts at
month 3 among participants in East Africa by sex and
infecting subtype.) Because preseroconversion CD4þ cell
counts were not available, it is difficult to determine
whether this lower CD4þ cell count predated HIV
acquisition. However, a study of laboratory references
ranges in healthy, HIV-uninfected African adults of
comparable age groups also sponsored by IAVI and
conducted at six of the CRCs participating in this study
showed no significant differences in median CD4þ cell
counts by geographic region, suggesting that preinfection
CD4þ cell counts may not significantly differ in this study
[31].
Kaleebu and Kiwanuka have reported faster disease
progression with subtype D versus A infections partially
explained by co-receptor tropism [15,21]. Baeten et al.
[32] found no difference between subtype C and Ahorized reproduction of this article is prohibited.
Co
2784 AIDS 2013, Vol 27 No 17infections, but the study sample size was modest. The
dominance of HIV-1 subtype C in much of Africa and
Asia has caused speculation that the overall pathogen-
icity or transmissibility of subtype C is greater than
other subtypes [33]. We showed that infection with
subtype C is associated with a more rapid virologic
disease progression, and high viral load is known to be
associated with increased transmission [34]. A study of
Zambian participants in this cohort showed that viral
load of both the transmitter and the newly infected
partner is predicted, at least in part, by the intrinsic
replication capacity of the transmitted subtype C virus
[35]. A similar evaluation of subtype A virus will be
of interest.
Study bias may have arisen in a number of ways.
Differences in clinical evaluation across CRCs may have
introduced misclassification bias in clinical endpoints.
Most Kenyan participants were MSM, who tend to delay
ART initiation and may not have optimal health seeking
behaviors due at least in part to stigma [36]. Pol
sequencing for subtype determination does not detect
recombinants in env or other regions. However, missed
recombinations in other genes should have been
randomly distributed. Specimens from participants with
delayed enrolment were sequenced at a longer time from
EDI. Interclade recombinants from superinfection or dual
infection, while uncommon, are probably more frequent
in East Africa than Southern Africa with more than 99%
subtype C.
Selection bias is also possible. CRCs differed in duration
of follow-up, time fromEDI to studyenrolment, age, sex,
and risk groups. Healthier participants may have out-
migrated for work and rapid progressors may have
initiated ART or been too ill to enroll; however,
sensitivity analyses between participants with delayed
versus immediate enrolment produced no significant
changes to our conclusions. Because of the strong
association between HIV-1 infecting subtype and
geographic region, the faster disease progression
observed among subtype C-infected participants could
be due to population differences for which we could not
adequately control. Additionally, the modest number of
subtype D-infected participants somewhat limited our
ability to evaluate comparative disease progression in
this subgroup.
In the context of a diverse HIV-1 genome, understanding
the role of infecting subtype on disease progression is
essential to guide public health policy, plan regionally
appropriate HIV care and treatment programs, and define
appropriate populations and endpoints for HIV preven-
tion efficacy trials. Our findings also suggest that
monitoring a relative loss of CD4 þcell count per
volunteer may also be informative, as time to a CD4þ cell
count threshold may be confounded by infecting subtype,
age, and sex.pyright © Lippincott Williams & Wilkins. UnauthoIdentifying individuals with early HIV infection, while
challenging, creates great opportunity for immunologic
and genetic investigation, along with the potential for
health benefits and reduction of HIV transmission.
Substantial investment in infrastructure, community and
national level engagement, and access to services
are prerequisites to establish longstanding, prospective
cohorts in resource-poor settings. Additional benefits of
this work include both the establishment of HIV
incidence cohorts suitable for efficacy trials of HIV
prevention interventions in diverse at-risk populations
and the collection of specimens that will contribute
to improved understanding of the HIV immunology,
virology, and pathology, including acute infection,
development of broadly neutralizing HIV antibodies,
and development and evaluation of new assays [37–39].
Observational epidemiology provides ideal research
platforms and facilitates HIV care [40].
Conclusion
Our study demonstrates subtype-specific differences in
HIV disease progression. To guide public health policy
and clinical trial design, it is essential to understand the
virologic, immunologic and clinical events that occur by
infecting HIV-1 subtype. Our work suggests that HIV
vaccine efficacy and relevant prevention trials should
include diverse HIV-1 subtypes, have adequate sample
sizes to evaluate this viral diversity, and consider potential
subtype-specific differences when defining clinical end-
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